27045425 29194389 25966836 32106141 26279978 33587507 25565175 32486903 29749896 29801580 27542768 30235109 35514050 29868865 29666902 33805706 29945900 27976978 26779253 28931220 34335044 26602158 29855606 26991336 30218255 27509478 27799204 2711011 - Search Results

Year	Number of Results
2014	1
2015	9
2016	12
2017	8
2018	9
2019	3
2020	2
2021	4
2022	1

1

CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.

Mukonzo JK, Bisaso RK, Ogwal-Okeng J, Gustafsson LL, Owen JS, Aklillu E. Mukonzo JK, et al. Pharmacogenomics. 2016 Apr;17(6):603-13. doi: 10.2217/pgs.16.7. Epub 2016 Apr 5. Pharmacogenomics. 2016. PMID: 27045425

2

Variation in CYP2A6 Activity and Personalized Medicine.

Tanner JA, Tyndale RF. Tanner JA, et al. J Pers Med. 2017 Dec 1;7(4):18. doi: 10.3390/jpm7040018. J Pers Med. 2017. PMID: 29194389 Free PMC article. Review.

3

PharmGKB summary: Efavirenz pathway, pharmacokinetics.

McDonagh EM, Lau JL, Alvarellos ML, Altman RB, Klein TE. McDonagh EM, et al. Pharmacogenet Genomics. 2015 Jul;25(7):363-76. doi: 10.1097/FPC.0000000000000145. Pharmacogenet Genomics. 2015. PMID: 25966836 Free PMC article. Review. No abstract available.

4

Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.

Haas DW, Cramer YS, Godfrey C, Rosenkranz SL, Aweeka F, Berzins B, Coombs R, Coughlin K, Moran LE, Gingrich D, Zorrilla CD, Baker P, Cohn SE, Scarsi KK; AIDS Clinical Trials Group A5316 Study Team. Haas DW, et al. Pharmacogenet Genomics. 2020 Apr;30(3):45-53. doi: 10.1097/FPC.0000000000000396. Pharmacogenet Genomics. 2020. PMID: 32106141 Free PMC article. Clinical Trial.

5

Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.

Asensi V, Collazos J, Valle-Garay E. Asensi V, et al. World J Virol. 2015 Aug 12;4(3):169-77. doi: 10.5501/wjv.v4.i3.169. World J Virol. 2015. PMID: 26279978 Free PMC article.

6

Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV.

Huang SH, Huang WC, Lin SW, Chuang YC, Sun HY, Chang SY, Kuo PH, Wu PY, Liu WC, Chiang C, Hung CC, Chang SC. Huang SH, et al. J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):834-841. doi: 10.1097/QAI.0000000000002650. J Acquir Immune Defic Syndr. 2021. PMID: 33587507

7

Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.

Haas DW, Tarr PE. Haas DW, et al. Curr Opin HIV AIDS. 2015 Mar;10(2):116-22. doi: 10.1097/COH.0000000000000134. Curr Opin HIV AIDS. 2015. PMID: 25565175 Free PMC article. Review.

8

Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters.

Kim V, Wal TV, Nishi MY, Montenegro LR, Carrilho FJ, Hoshida Y, Ono SK. Kim V, et al. Pharmacogenomics. 2020 Jun;21(9):575-586. doi: 10.2217/pgs-2020-0013. Epub 2020 Jun 3. Pharmacogenomics. 2020. PMID: 32486903 Free PMC article.

9

A pharmacist's role in the individualization of treatment of HIV patients.

Hernández Arroyo MJ, Cabrera Figueroa SE, Valverde Merino MP, Hurlé AD. Hernández Arroyo MJ, et al. Per Med. 2016 Mar;13(2):169-188. doi: 10.2217/pme.15.54. Per Med. 2016. PMID: 29749896

10

Cytochrome P450 in Pharmacogenetics: An Update.

Tornio A, Backman JT. Tornio A, et al. Adv Pharmacol. 2018;83:3-32. doi: 10.1016/bs.apha.2018.04.007. Adv Pharmacol. 2018. PMID: 29801580 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results